Opening Statement from the January 2021 Intelligent Investor (part 1)

Opening Statement from the January 2021 Intelligent Investor (part 1)

Originally published on January 6, 2021 (pre-market release)

Coronavirus Risks

In late March 2020 I expressed my confidence that a vaccine would be developed before the end of 2020. This view was in stark contrast to all of the “experts” who insisted that a vaccine would not be developed until mid-2021 (best-case) or late 2021 (consensus).

In addition to our recommendations in March 2020 (special webinars and securities research) to overweigh large cap pharma and biopharma stocks, I selected Moderna (MRNA) as the best risk-reward newer small cap biotech as one to consider investing in. Since then, it rose by nearly 600 percent.

I also warned about potential issues with vaccines as well as the likelihood of mutations during the March 2020 coronavirus webinar presentations. Just as I predicted in March 2020, we are now seeing different strains of coronavirus due to mutations.

We do not yet know how effective the vaccines will be against COVID-19. But clearly, the appearance of mutations has already presented a significant risk moving forward.

In March 2020 I also began to discuss the risk of vaccine reluctance from significant numbers of certain populations (especially in the U.S). Although many concerns about the safety of the vaccines are valid, there is a particularly large and growing movement of disinformation from conspiracy nuts and profiteers. If you follow the content on our website you know who some of these individuals are.